CU20120118A7 - Compuestos bicíclicos y sus usos como inhibidores duales de c-src/jak - Google Patents

Compuestos bicíclicos y sus usos como inhibidores duales de c-src/jak

Info

Publication number
CU20120118A7
CU20120118A7 CU2012000118A CU20120118A CU20120118A7 CU 20120118 A7 CU20120118 A7 CU 20120118A7 CU 2012000118 A CU2012000118 A CU 2012000118A CU 20120118 A CU20120118 A CU 20120118A CU 20120118 A7 CU20120118 A7 CU 20120118A7
Authority
CU
Cuba
Prior art keywords
src
inhibitors
jak
present
compounds
Prior art date
Application number
CU2012000118A
Other languages
English (en)
Inventor
Allister Andrés Mc
Maximilien Murone
Saumitra Sengupta
Shankar Jayaram Shetty
Original Assignee
Debiopharm Sa
Aurigene Discovery Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm Sa, Aurigene Discovery Tech Ltd filed Critical Debiopharm Sa
Publication of CU20120118A7 publication Critical patent/CU20120118A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos bicíclicos aromáticos sustituidos que contienen anillos de pirimidina y piridina así como también sales aceptables para uso farmacéuticos de los mismos.Los compuestos de la presente invención son útiles como inhibidores de la tirosina quinasa, con preferencia inhibidores de la familia SRC de las quinasas( SFK), en particular como inhibidores múltiples de la SFK/JAK quinasas e incluso, con preferencia, como inhibidores duales de las c- SRC/JAK quinasas, inhibiendo así la activación de STAT3 y, por lo tanto, el crecimiento anormal de los tipos celulares particulares.Notablemente, los compuestos de la presente invención son útiles para el tratamiento o inhibición de ciertas enfermedades que son el resultado de la desregulación de STAT3.
CU2012000118A 2010-02-17 2012-08-15 Compuestos bicíclicos y sus usos como inhibidores duales de c-src/jak CU20120118A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN415CH2010 2010-02-17
PCT/IB2011/050669 WO2011101806A1 (en) 2010-02-17 2011-02-17 Bicyclic compounds and their uses as dual c-src / jak inhibitors

Publications (1)

Publication Number Publication Date
CU20120118A7 true CU20120118A7 (es) 2012-10-15

Family

ID=43903941

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2012000118A CU20120118A7 (es) 2010-02-17 2012-08-15 Compuestos bicíclicos y sus usos como inhibidores duales de c-src/jak

Country Status (28)

Country Link
US (2) US8440679B2 (es)
EP (1) EP2536722B1 (es)
JP (1) JP2013519725A (es)
KR (1) KR20120130294A (es)
CN (1) CN102858770A (es)
AR (1) AR089641A1 (es)
AU (1) AU2011216895B2 (es)
BR (1) BR112012020639A2 (es)
CA (1) CA2789655A1 (es)
CU (1) CU20120118A7 (es)
CY (1) CY1115420T1 (es)
DK (1) DK2536722T3 (es)
EA (1) EA201290757A1 (es)
ES (1) ES2470190T3 (es)
HR (1) HRP20140437T1 (es)
IL (1) IL221487A (es)
MX (1) MX2012009482A (es)
NZ (1) NZ602271A (es)
PH (1) PH12012501654A1 (es)
PL (1) PL2536722T3 (es)
PT (1) PT2536722E (es)
RS (1) RS53458B (es)
SA (1) SA111320200B1 (es)
SG (1) SG183329A1 (es)
SI (1) SI2536722T1 (es)
SM (1) SMT201400090B (es)
TW (1) TW201130838A (es)
WO (1) WO2011101806A1 (es)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103214484B (zh) 2005-12-13 2016-07-06 因塞特控股公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
HUE029236T2 (en) 2007-06-13 2017-02-28 Incyte Holdings Corp (R) -3- (4- (7H-Pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile Crystalline salts of Janus kinase inhibitor
EP2432472B1 (en) 2009-05-22 2019-10-02 Incyte Holdings Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
EP3354652B1 (en) 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
AR084691A1 (es) 2010-05-21 2013-06-05 Incyte Corp Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
WO2013138396A1 (en) 2012-03-12 2013-09-19 Allergan, Inc. Dihydropyridopyrimidine and dihydronaphthyridine derivatives as tyrosine kinase inhibitors of especially vegf and pdgf
US9388176B2 (en) 2012-03-12 2016-07-12 Allergan, Inc. Method of treating conditiions with kinase inhibitors
LT3495367T (lt) 2012-06-13 2021-02-25 Incyte Holdings Corporation Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
TWI761825B (zh) 2012-11-15 2022-04-21 美商英塞特控股公司 盧梭利替尼之緩釋性劑型
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
EP4282419A1 (en) 2012-12-20 2023-11-29 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
US20160123982A1 (en) 2013-02-04 2016-05-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for assaying jak2 activity in red blood cells and uses thereof
MX384910B (es) 2013-03-06 2025-03-14 Incyte Holdings Corp Procesos e intermedios para hacer un inhibidor de jak.
LT2986610T (lt) 2013-04-19 2018-04-10 Incyte Holdings Corporation Bicikliniai heterociklai, kaip fgfr inhibitoriai
WO2014196793A1 (en) * 2013-06-05 2014-12-11 C&C Research Laboratories Heterocyclic derivatives and use thereof
SG11201600815WA (en) 2013-08-07 2016-03-30 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
AU2015209239C1 (en) 2014-01-24 2026-05-07 Turning Point Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
JP6783224B2 (ja) 2014-04-04 2020-11-11 デル マー ファーマシューティカルズ 肺の非小細胞癌腫及び卵巣癌を処置するためのジアンヒドロガラクチトール及びその類縁体又は誘導体の使用
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
US9321766B1 (en) 2014-10-06 2016-04-26 Allergan, Inc. Kinase inhibitors
US9296747B1 (en) 2014-10-10 2016-03-29 Allergan, Inc. Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
SG11201706287PA (en) 2015-02-20 2017-09-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MX2017017097A (es) 2015-07-02 2018-05-23 Tp Therapeutics Inc Macrociclos diarílicos quirales como moduladores de proteínas quinasas.
PL3319969T3 (pl) 2015-07-06 2024-06-24 Turning Point Therapeutics, Inc. Diarylowe polimorfy makrocykliczne
LT3733187T (lt) 2015-07-21 2024-12-10 Turning Point Therapeutics, Inc. Chiralinis diarilo makrociklas ir jo panaudojimas vėžio gydymui
US12144850B2 (en) 2016-04-08 2024-11-19 Purdue Research Foundation Methods and compositions for car T cell therapy
CN107459519A (zh) 2016-06-06 2017-12-12 上海艾力斯医药科技有限公司 稠合嘧啶哌啶环衍生物及其制备方法和应用
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
AU2018219226B2 (en) 2017-02-07 2024-12-19 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
EP3610264A1 (en) 2017-04-13 2020-02-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2018222917A1 (en) * 2017-06-01 2018-12-06 Quentis Therapeutics, Inc. Ire1 small molecule inhibitors
JP7126084B2 (ja) 2017-06-01 2022-08-26 コーネル ユニバーシティー Ｉｒｅ１小分子阻害薬
US10392367B2 (en) 2017-06-01 2019-08-27 Quentis Therapeutics, Inc. IRE1 small molecule inhibitors
CA3069232A1 (en) 2017-07-28 2019-01-31 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
HUE060711T2 (hu) 2017-12-19 2023-04-28 Turning Point Therapeutics Inc Makrociklusos vegyületek betegségek kezelésére
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
JP7393348B2 (ja) 2018-01-30 2023-12-06 インサイト・コーポレイション （１－（３－フルオロ－２（トリフルオロメチル）イソニコチニル）ピぺリジン―４－オン）を作製するためのプロセス及び中間体
WO2019156795A1 (en) 2018-02-06 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
CA3091674A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
CN113768934A (zh) 2018-03-30 2021-12-10 因赛特公司 使用jak抑制剂治疗化脓性汗腺炎
MX2020011718A (es) 2018-05-04 2021-02-15 Incyte Corp Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas.
ES3061844T3 (en) 2018-05-04 2026-04-07 Incyte Corp Salts of an fgfr inhibitor
CN109180657A (zh) * 2018-10-31 2019-01-11 南京先进生物材料与过程装备研究院有限公司 Stat3抑制剂的制备方法
CN109336868A (zh) * 2018-10-31 2019-02-15 南京先进生物材料与过程装备研究院有限公司 吲哚类stat3抑制剂及其制备方法
CN109485643A (zh) * 2018-10-31 2019-03-19 南京先进生物材料与过程装备研究院有限公司 一种芴酮类stat3抑制剂及制备方法与应用
CN109369627A (zh) * 2018-10-31 2019-02-22 南京先进生物材料与过程装备研究院有限公司 芴酮类stat3抑制剂晶型a及制备方法
CN109293641A (zh) * 2018-10-31 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种芴类stat3抑制剂及其制备方法
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2022549506A (ja) 2019-09-27 2022-11-25 ディスク・メディシン・インコーポレイテッド 骨髄線維症および関連状態を処置するための方法
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
TWI891666B (zh) 2019-10-14 2025-08-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之雙環雜環
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
KR20220163940A (ko) 2020-02-04 2022-12-12 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 항-디니트로페놀 키메라 항원 수용체
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環
EP4352060A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4349472A (en) 1979-04-27 1982-09-14 Schering Corporation (S)-8(1-Adamantanecarbonyloxy)-7-chloro-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
EE200000706A (et) * 1998-05-26 2002-06-17 Warner-Lambert Company Bitsüklilised pürimidiinid ja bitsüklilised 3,4-dihüdropürimidiinid kui rakkude proliferatsiooni inhibiitorid
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
EP1345925B1 (en) * 2000-12-21 2006-05-17 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP4758349B2 (ja) * 2003-10-08 2011-08-24 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
AU2007211684A1 (en) * 2006-01-31 2007-08-09 F. Hoffmann-La Roche Ag 7H-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors
WO2008077062A2 (en) 2006-12-19 2008-06-26 Board Of Regents, The University Of Texas System Suppression of stat3 reactivation after src kinase inhibition to treat cancer
HUE029236T2 (en) 2007-06-13 2017-02-28 Incyte Holdings Corp (R) -3- (4- (7H-Pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile Crystalline salts of Janus kinase inhibitor
WO2009029998A1 (en) 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Retrometabolic compounds
GB2467670B (en) * 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
US8183245B2 (en) 2007-10-25 2012-05-22 Merck Sharp & Dohme Corp. Pyrazine substituted pyrrolopyridines as inhibitors of JAK and PDK1
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة

Also Published As

Publication number Publication date
NZ602271A (en) 2013-09-27
SA111320200B1 (ar) 2014-02-16
EP2536722B1 (en) 2014-04-16
MX2012009482A (es) 2012-11-29
US8962637B2 (en) 2015-02-24
US8440679B2 (en) 2013-05-14
SI2536722T1 (sl) 2014-10-30
US20130143895A1 (en) 2013-06-06
KR20120130294A (ko) 2012-11-30
SG183329A1 (en) 2012-09-27
ES2470190T3 (es) 2014-06-23
CA2789655A1 (en) 2011-08-25
SMT201400090B (it) 2014-09-08
JP2013519725A (ja) 2013-05-30
CN102858770A (zh) 2013-01-02
AU2011216895B2 (en) 2015-11-05
RS53458B (sr) 2014-12-31
DK2536722T3 (da) 2014-05-26
PL2536722T3 (pl) 2014-11-28
TW201130838A (en) 2011-09-16
BR112012020639A2 (pt) 2017-08-08
WO2011101806A1 (en) 2011-08-25
US20130012518A1 (en) 2013-01-10
PH12012501654A1 (en) 2018-02-07
HK1178897A1 (en) 2013-09-19
PT2536722E (pt) 2014-05-26
AU2011216895A1 (en) 2012-09-27
EA201290757A1 (ru) 2013-04-30
CY1115420T1 (el) 2017-01-04
IL221487A (en) 2014-11-30
AR089641A1 (es) 2014-09-10
HRP20140437T1 (hr) 2014-08-29
EP2536722A1 (en) 2012-12-26

Similar Documents

Publication Publication Date Title
BR112012020639A2 (pt) compostos biciclicos e seus usos como duplo inibidores de c-src/jak.
CU20130115A7 (es) Compuestos y composiciones como inhibidores de trk
CR20150371A (es) Inhibidores de prmt5 y sus usos
DOP2014000188A (es) Derivados macrocíclicos para el tratamiento de enfermedades
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
CR11650A (es) DERIVADOS BICICLICOS HETEROCICLICOS O ESPIROBICICLICOS HETEROCICLICOS ENLAZADOS, DE PIRAZOLO[1,5-a] PIRIMIDINAS, PROCEDIMIENTOS PARA SU PREPARACION Y USOS DE LOS MISMOS
MX2013001970A (es) Compuestos de pirrolopirimidina y usos de los mismos.
MX339937B (es) Compuestos y composiciones como inhibidores de la quinasa c-kit.
PH12014500351B1 (en) COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS
MX345830B (es) Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y metodos para su uso.
MX361815B (es) Compuestos pirazolopirimidinicos como inhibidores de cinasas.
CR20140223A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
UY35249A (es) Inhibidores del receptor del factor de crecimiento de fibroblastos
MX2019003468A (es) Derivados de tieno [3,2-d]pirimidina que tienen actividad inhibidora de las cinasas de proteina.
UY31821A (es) Compuestos y composiciones como inhibidores de quinasa
BR112015019508A8 (pt) formas sólidas de um inibidor de cdk4/6 seletivo
MX2015012867A (es) Compuestos aromaticos multisustituidos como inhibidores de serina proteasa.
CO6620050A2 (es) Derivados de aminopirimidina como moduladores de la lrrk2
CR20140031A (es) Derivados de piridin-2(1h)-ona como inhibidores de jak
PA8834001A1 (es) Compuestos y composiciones como inhibidores de cinasa
CL2012000589A1 (es) Compuestos derivados de pirrolo piridin carboxamidas, inhibidores de jak2; composición farmacéutica que los comprende; uso en el tratamiento de enfermedades mieloproliferativas o cáncer, tales como policitemia vera, trombocitopenia esencial, mieloma múltiple, entre otras.
NI201200029A (es) Compuestos y composiciones como inhibidores de cinasa de proteína
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
CO6680703A2 (es) Derivados de 6,7-dihidro-3h-oxazolo(3,4-a)pirazin-5,8-diona
CU20140107A7 (es) Derivados macrocíclicos para el tratamiento de enfermedades